EUCTR2013-001640-56-ES
Active, not recruiting
Not Applicable
Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibition of xanthine oxidase.
Fundación Para la Investigación Biomédica de Córdoba0 sitesSeptember 16, 2013
ConditionsPatients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.MedDRA version: 16.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
- Sponsor
- Fundación Para la Investigación Biomédica de Córdoba
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patient willing and able to give informed consent for participation in the study.
- •\- Ability to understand study procedures and to comply with it for the duration of the study.
- •\- Subjects of both sexes, the age range between 18 and 70 years old.
- •\- Serum uric acid than 7 mg / dl.
- •\- Estimated glomerular filtration rate by MDRD abbreviated formula less than 60 ml / min/1\.73m2 and above 15 ml/min/1\.73m2\.
- •\- Stability of renal function (serum creatinine increase without exceeding 50% in the three months before the start of the study).
- •\- Clinically stable in terms of no hospitalizations or cardiovascular events in the 3 months before the study began.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •\- Drop active in the 60 days prior to study initiation.
- •\- Use of allopurinol within 60 days preceding baseline
- •\- Active infections within 30 days prior to baseline.
- •\- Patients with systemic inflammatory disease.
- •\- Infection with HIV, Hepatitis C and Hepatitis B.
- •\- History of cancer within 5 years prior to the first dose of study medication.
- •\- Chronic liver disease.
- •\- Immunosuppressive therapy.
- •\- Pregnant women, breastfeeding, or planning to become pregnant.
- •\- Allergy or sensitivity to allopurinol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Randomized, double blind, crossover clinical study to evaluate the sedative effect after the treatment of 1 mg dose of ketotifen, or 10 or 20 mg dose of cetirizine using saccadic eye movement analysis in healthy male volunteersJPRN-UMIN000004527Department of Clinical Pharmacy, School of Pharmacy, Showa University6
Completed
Phase 1
The effect of berryfruit extract on airways inflammation and airways obstruction in asthmaAsthmaRespiratory - AsthmaAlternative and Complementary Medicine - Other alternative and complementary medicineACTRN12613000451707The New Zealand Institute for Plant & Food Research Ltd28
Active, not recruiting
Not Applicable
A trial comparing the safety and efficacy of insulin degludec and insulin glargine, both with insulin aspart as mealtime insulin in subjects with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 17.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2012-001930-32-PLovo Nordisk A/S446
Active, not recruiting
Not Applicable
A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)Seasonal allergic rhinitisMedDRA version: 9.1Level: LLTClassification code 10039776Term: Seasonal allergic rhinitisEUCTR2007-005302-44-ATGlaxoSmithKline Research & Development Limited70
Active, not recruiting
Not Applicable
A controlled, randomized, double-blind, cross-over study of the onset of analgesic effect of two formulations of ibuprofen for the treatment of pain after oral surgery.PainMedDRA version: 12.0Level: LLTClassification code 10033371Term: PainEUCTR2009-015589-74-SEycomed Sweden Holding 2 AB140